WILMINGTON, Mass., Aug. 6 DUSA Pharmaceuticals, Inc. (Nasdaq GM: DUSA) announces that its corporate highlights and second quarter financial results press release will be issued on Tuesday, August 11 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Advertisement
Tuesday, August 11 - 8:30 a.m. E.T.
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA
Advertisement
For International callers use
502.498.8422
A recorded replay of the call will be available approximately 15 minutes following the call
North American callers 877.863.0350
International callers 858.244.1268
The call will be accessible on our web site approximately four hours following the call at www.dusapharma.com.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(R) photodynamic therapy (PDT) technology platform, and complementary dermatology products. Levulan(R) PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(R). DUSA is researching Levulan(R) PDT for the treatment of AKs and the reduction of new non-melanoma skin cancer (NMSC) in chronically immunosuppressed solid organ transplant recipients (SOTRs). In addition, DUSA is supporting research related to oral leukoplakia in collaboration with National Institutes of Health (NIH). DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.
SOURCE DUSA Pharmaceuticals, Inc.
